<DOC>
	<DOCNO>NCT00117156</DOCNO>
	<brief_summary>The purpose study determine effectiveness six cycle concurrent fludarabine rituximab patient mucosa-associated lymphoid tissue ( MALT ) lymphoma , marginal zone lymphoma ( MZL ) CD5- , CD10- , CD20+ low-grade B cell lymphoma .</brief_summary>
	<brief_title>Fludarabine Rituximab Treatment Marginal Zone Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Objectives : Primary - To estimate objective response rate . Secondary - To assess safety . - To describe progression-free survival one year . - To examine association clonal cytogenetic abnormality identify FISH , objective response rate well progression-free survival one year . Target enrollment 30 eligible patient . An 80 % objective response rate 1 month restaging 6 cycle consider evidence activity patient population 60 % consider activity . If least 22 patient achieve objective response treatment would consider promising . With 30 eligible patient , probability observe 0.87 assume true rate 80 % 0.09 assume true rate 60 % .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Histologically confirm , newly diagnose relapsed MALT , marginal zone lymphoma , lowgrade B cell lymphoproliferative disorder CD5 , CD10 CD20+ Pathology must review Brigham &amp; Women 's Hospital , Massachusetts General Hospital , University Rochester James P. Wilmot Cancer Center prior enrollment Documentation CD20+ status Must candidate local radiotherapy curative intent If gastric MALT , candidate antibiotic therapy curative intent Patients leukemic phase marginal zone lymphoma eligible absolute lymphocyte count &gt; 10,000 / Âµl Prior treatment rituximab permit , rituximab induce objective response persist least 6 month Prior radiotherapy acceptable Measurable disease ANC : &gt; 1000/mm3 Platelets : &gt; 100,000/mm3 Hemoglobin : &gt; 7 gm/dL Adequate renal function indicate serum creatinine &lt; = 2 mg/dL . Adequate liver function , indicate serum total bilirubin &lt; = 2 mg/dL . AST ALT &lt; 3x Upper Limit Normal unless related primary disease . Men woman reproductive potential must agree use acceptable method birth control study treatment six month completion study treatment . WHO Performance status &lt; /= 2 Subject provide write informed consent . Patients Waldenstrom 's Macroglobulinemia lymphoplasmacytic lymphoma exclude History HIV Active infection Known CNS disease Pregnant ( negative serum pregnancy test perform woman childbearing potential within 7 day treatment ) currently lactate woman Prior treatment within last three week Prior fludarabine Positive direct antiglobulin test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Fludarabine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Marginal Zone Lymphoma</keyword>
	<keyword>MALT lymphoma</keyword>
</DOC>